These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28166158)

  • 21. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.
    Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L
    J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
    Robbins RJ; Tuttle RM; Sharaf RN; Larson SM; Robbins HK; Ghossein RA; Smith A; Drucker WD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):619-25. PubMed ID: 11158019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer.
    Serhal DI; Nasrallah MP; Arafah BM
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3285-9. PubMed ID: 15240604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
    Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
    Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.
    Luster M; Sherman SI; Skarulis MC; Reynolds JR; Lassmann M; Hänscheid H; Reiners C
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1371-7. PubMed ID: 12856155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Recombinant human TSH stimulation in radioiodine treatment of disseminated differentiated thyroid cancer--update of current and our own experiences].
    Hasse-Lazar K; Handkiewicz-Junak D; Roskosz J; Szpak-Ulczok S; Krajewska J; Jurecka-Lubieniecka B; Jarzab B
    Endokrynol Pol; 2006; 57(4):445-50. PubMed ID: 17006851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine.
    Robbins RJ; Driedger A; Magner J;
    Thyroid; 2006 Nov; 16(11):1121-30. PubMed ID: 17123339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
    Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
    Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
    Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
    J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Patients With Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy.
    Zhao T; Liang J; Guo Z; Li T; Lin Y
    Clin Nucl Med; 2016 Jun; 41(6):454-8. PubMed ID: 26914559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.
    Tu J; Wang S; Huo Z; Lin Y; Li X; Wang S
    Radiother Oncol; 2014 Jan; 110(1):25-30. PubMed ID: 24485353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism.
    Ringel MD; Ladenson PW
    J Clin Endocrinol Metab; 1996 May; 81(5):1724-5. PubMed ID: 8626823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human thyrotropin versus thyroid hormone withdrawal in an Asian population.
    Tang CYL; Thang SP; Zaheer S; Kwan CK; Ng DC
    Endocrine; 2020 Jul; 69(1):126-132. PubMed ID: 32112240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
    Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
    Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Timing of Hormone Withdrawal in Children Undergoing 131I Whole-Body Scans for Thyroid Cancer.
    Turpin S; Lambert R; Deal C
    Horm Res Paediatr; 2016; 86(6):410-415. PubMed ID: 27902975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States.
    Wang TS; Cheung K; Mehta P; Roman SA; Walker HD; Sosa JA
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1672-80. PubMed ID: 20139234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
    Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J
    Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study.
    Luster M; Handkiewicz-Junak D; Grossi A; Zacharin M; Taïeb D; Cruz O; Hitzel A; Casas JA; Mäder U; Dottorini ME;
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3948-53. PubMed ID: 19773393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.